Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rödjer, S.
Right arrow Articles by Westin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rödjer, S.
Right arrow Articles by Westin, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1987) 20, 109-116
© 1987 The British Society for Antimicrobial Chemotherapy

research-article

Treatment of septicaemia in immunocompromised patients with ceftazidime or with tobramycin and cefuroxime, with special reference to renal effects

S. Rödjer, K. Alestig, J. Bergmark, T. Bergström, B. Hultberg, R. Jagenburg, L. Olaisson, B. Trollfors and J. Westin

Departments of Medicine, Infectious Diseases and Clinical Chemistry, Gothenburg University Östra Hospital S-416 85 Goteborg Department of Clinical Chemistry, University of Lund Sweden

accepted 11 February 1987

Fifty-two immunocompromised patients with suspected septicaemia were randomized on 61 occasions to treatment with ceftazidime or with tobramycin and cefuroxime. Most (90%) of the patients had haematological malignancies and were neutropenic (granulocytes <1 x 109/l in 40 of the 61 episodes). Blood cultures were positive in 22 (39%) febrile episodes and in four other instances positive cultures were obtained from other sources. Clinical cure or improvement was noted in 10 of 12 culture verified infections in the tobramycin and cefuroxime group and 11 of 14 episodes in the ceftazidime-group.

The effect on the kidney of the two antibiotic regimens was studied by following the serum levels of creatinine, urea and ß2-microglobulin and the urinary excretion of alanine aminopeptidase, Nacetyl-ß-D-glucosaminidase (ß-NAG) and ß2-microglobulin. No clinically important renal side effects were observed. However, an increase in the urinary excretion of AAP was seen in both groups with significantly greater elevation in the tobramycin and cefuroxime group. Urinary ß-NAG increased only in the tobramycin and cefuroxime group.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.